PIK3CG and neoplasm: In addition, ribociclib has shown anti-tumor activity when combined with targeted agents which inhibit signaling pathways known to regulate D-cyclin levels, including inhibitors of the RAF, mitogen-activated protein kinase kinase (MEK), phosphoinositide 3-kinase (PIK3), and mammalian target of rapamycin (mTOR) pathways [35,39,40].